These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 28846017)

  • 1. Pharmacologic Treatment of Wet Type Age-related Macular Degeneration; Current and Evolving Therapies.
    Shams Najafabadi H; Daftarian N; Ahmadieh H; Soheili ZS
    Arch Iran Med; 2017 Aug; 20(8):525-537. PubMed ID: 28846017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging pharmacologic therapies for wet age-related macular degeneration.
    Ni Z; Hui P
    Ophthalmologica; 2009; 223(6):401-10. PubMed ID: 19622904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AMD--the retinal disease with an unprecised etiopathogenesis: in search of effective therapeutics.
    Nowak JZ
    Acta Pol Pharm; 2014; 71(6):900-16. PubMed ID: 25745762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration.
    Schmidt-Erfurth U; Waldstein SM; Deak GG; Kundi M; Simader C
    Ophthalmology; 2015 Apr; 122(4):822-32. PubMed ID: 25578255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in pharmacotherapy for wet age-related macular degeneration.
    Santarelli M; Diplotti L; Samassa F; Veritti D; Kuppermann BD; Lanzetta P
    Expert Opin Pharmacother; 2015; 16(12):1769-81. PubMed ID: 26165696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining response to anti-VEGF therapies in neovascular AMD.
    Amoaku WM; Chakravarthy U; Gale R; Gavin M; Ghanchi F; Gibson J; Harding S; Johnston RL; Kelly SP; Lotery A; Mahmood S; Menon G; Sivaprasad S; Talks J; Tufail A; Yang Y
    Eye (Lond); 2015 Jun; 29(6):721-31. PubMed ID: 25882328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-related macular degeneration therapy: a review.
    Ammar MJ; Hsu J; Chiang A; Ho AC; Regillo CD
    Curr Opin Ophthalmol; 2020 May; 31(3):215-221. PubMed ID: 32205470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VITREOMACULAR TRACTION AFFECTS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OUTCOMES FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
    Krishnan R; Arora R; De Salvo G; Stinghe A; Severn PS; Pal B; Goverdhan S
    Retina; 2015 Sep; 35(9):1750-6. PubMed ID: 26237240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial.
    Abdelfattah NS; Al-Sheikh M; Pitetta S; Mousa A; Sadda SR; Wykoff CC;
    Ophthalmology; 2017 Feb; 124(2):215-223. PubMed ID: 27863845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugs in Phase II clinical trials for the treatment of age-related macular degeneration.
    Tolentino MJ; Dennrick A; John E; Tolentino MS
    Expert Opin Investig Drugs; 2015 Feb; 24(2):183-99. PubMed ID: 25243494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neovascular Age-Related Macular Degeneration.
    Shao J; Choudhary MM; Schachat AP
    Dev Ophthalmol; 2016; 55():125-36. PubMed ID: 26501146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation studies of ranibizumab for neovascular age-related macular degeneration.
    Bloch SB
    Acta Ophthalmol; 2013 Nov; 91 Thesis7():1-22. PubMed ID: 24206851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging roles of transforming growth factor β signaling in wet age-related macular degeneration.
    Wang K; Li H; Sun R; Liu C; Luo Y; Fu S; Ying Y
    Acta Biochim Biophys Sin (Shanghai); 2019 Jan; 51(1):1-8. PubMed ID: 30496406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy.
    de Oliveira Dias JR; Rodrigues EB; Maia M; Magalhães O; Penha FM; Farah ME
    Br J Ophthalmol; 2011 Dec; 95(12):1631-7. PubMed ID: 21546514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel and investigational therapies for wet and dry age-related macular degeneration.
    Sarkar A; Jayesh Sodha S; Junnuthula V; Kolimi P; Dyawanapelly S
    Drug Discov Today; 2022 Aug; 27(8):2322-2332. PubMed ID: 35460893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-VEGF response in macular hemorrhage and incidence of retinal pigment epithelial tears.
    Varshney N; Jain A; Chan V; Yu L; Sarraf D
    Can J Ophthalmol; 2013 Jun; 48(3):210-5. PubMed ID: 23769784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration.
    Munk MR; Ceklic L; Ebneter A; Huf W; Wolf S; Zinkernagel MS
    Acta Ophthalmol; 2016 Dec; 94(8):e757-e764. PubMed ID: 27417506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exacerbation of choroidal and retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.
    Young M; Chui L; Fallah N; Or C; Merkur AB; Kirker AW; Albiani DA; Forooghian F
    Retina; 2014 Jul; 34(7):1308-15. PubMed ID: 24451923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging therapies for the treatment of neovascular age related macular degeneration.
    Yuan A; Kaiser PK
    Semin Ophthalmol; 2011 May; 26(3):149-55. PubMed ID: 21609228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ganglion Cell Complex Evaluation in Exudative Age-Related Macular Degeneration after Repeated Intravitreal Injections of Ranibizumab.
    Perdicchi A; Peluso G; Iacovello D; Balestrieri M; Delle Fave M; Abdolrahimzadeh S; Scuderi GL; Fenicia V; Recupero SM
    Biomed Res Int; 2015; 2015():268796. PubMed ID: 26167478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.